]>
IRCT20200614047766N1 IRCT 2020-06-30 Arak University of Medical Sciences Investigation of the effect of curcumin in Multiple Sclerosis The effect of Curcumin on Oxidant , Antioxidant factors ,Liver ,Kidney tests serum , Clinical signs and symptoms of MultipleSclerosis patients 2020-09-21 anticipated 96 Complete https://irct.ir/trial/48888 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with divided randomization with block sizes of 4 and 6 blocks will be divided into two groups of cases (MS patients who will receive curcumin in 48 people) and Dardonema (MS patients who will receive placebo in 48 people). In this way, we paste 96 randomly selected codes on 96 cans of capsules that are similar in color, shape and size, and after pouring the curcumin capsule and placebo capsule according to the codes in the cans, we put all the cans. Pour into a bag, Blinding description: According to the codes we have, Razak's 370 mg curcumin capsules will initially be given twice daily to the CASE group and the placebo-containing placebo capsule to the placebo group by the doctor's secretary (who has no knowledge of the type of capsules or what group of patients are in which). In this way, the doctor, the researcher and the patient have no knowledge of the groups. 3 Multiple Sclerosis. Intervention 1: Intervention group: Intervention group: MS patients who take Corkomine oral capsule for 3 months at a dose of 370 mg, take one a day at the beginning of the study and then take it twice a day. It has high antioxidant properties. Intervention 2: Control group: MS patients who receive placebo for 3 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Zahra Goodarzi
No. 9881, 30 Shams Alley, Football Street
Arak Iran (Islamic Republic of) 3815899881 +98 86 3276 3858 kiyangolmohamadi@gmail.com Arak University of Medical Sciences scientific Alireza Rezaei Ashtiani
No.3345, Mir Ahmad Doctors Building,Adalat Alley, Shahid Beheshti St, Arak
Arak Iran (Islamic Republic of) ٣٨١٩٦٩٣٣٤٥ +98 86 3223 9388 farahaniheidar@yahoo.com Arak University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) The study subjects must have RRMS type Ms disease They are 18 to 50 years old and EDSS (disease incapacity severity) must be less than 4 Patients who have been diagnosed with MS for at least one year Patients who do not have a specific digestive problem (gastric and duodenal ulcers, irritable bowel syndrome, indigestion) Not sensitive to curcumin They do not receive zinc or selenium supplements Antioxidant corticosteroids, such as vitamin E-A-D, have not been used for at least the past two weeks. They are not pregnant Don't be a breastfeeding woman They do not have special liver or kidney problems 18 years 50 years Both Lack of willingness of the patient to continue cooperation patients with mental disorders G35 Demyelinating diseases of the central nervous system Treatment - Drugs Placebo Intervention group: Intervention group: MS patients who take Corkomine oral capsule for 3 months at a dose of 370 mg, take one a day at the beginning of the study and then take it twice a day. It has high antioxidant properties. Control group: MS patients who receive placebo for 3 months Total oxidative status. Timepoint: Measurement of total oxidative status at the beginning of the study (before the start of the intervention) and 3 months after the start of use of curcumin capsules. Method of measurement: Total Oxidative Status Measurement Kit. Malone Dialdehyde. Timepoint: Measurement of malondialdehyde at the beginning of the study (before the intervention) and 3 months after the start of use of curcumin capsules. Method of measurement: Malon dialdehyde Measurement Kit. آب اکسیژنه. Timepoint: Measurement of oxygenated water at the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: Oxygenated water measurement kit. Super Oxide Dismutase. Timepoint: Measurement of dismutase superoxide at the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: Dysmotase Super Oxide Measurement Kit. Glutathione Revival. Timepoint: Measurement of glutathione reductase at the beginning of the study (before the start of the intervention) and 3 months after the start of the use of curcumin capsules. Method of measurement: Glutathione Revitalization Measurement Kit. Aspartate amino transferase. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin. Method of measurement: Aspartate aminotransferase assay kit. Alanin amino transferase. Timepoint: The beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin. Method of measurement: Alanine Amino Transfer Measurement Kit. Blood creatinine. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin. Method of measurement: Creatine measuring kit. Nitrogen in the blood urea. Timepoint: At the beginning of the study and 3 months after taking curcumin. Method of measurement: Blood urea nitrogen measurement kit. Expanded Disability Status Scale. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: questionnaire. Fatigue Severity Scale. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: questionnaire. Gait disorder. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of use of curcumin capsules. Method of measurement: 25 foot test. Arak University of Medical Sciences Approved 2020-06-08 Ethics Committee of Arak University of Medical Sciences Deputy of Research and Technology, Payambar Azam University Complex, Basij Square, Sardasht St Arak Markazi Iran (Islamic Republic of)